Mature B-Cell Neoplasm
NCI Definition: A neoplasm that arises from mature B-lymphocytes or plasma cells. Representative examples include mature B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, hairy cell leukemia, and plasma cell neoplasms. 
Mature B-cell neoplasms most frequently harbor alterations in KMT2D, CREBBP, TP53, BCL2, and MYD88 .
KMT2D Mutation, CREBBP Mutation, TP53 Mutation, BCL2 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in mature B-cell neoplasm .
There is 1 clinical trial for mature B-cell neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains mature B-cell neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
Dihydroorotate dehydrogenase inhibitor is the most common intervention in mature B-cell neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.